Cyclic dinucleotide metal compound, and preparation and application thereof
US-2024317792-A1 · Sep 26, 2024 · US
US9402862B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9402862-B2 |
| Application number | US-87441710-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 2, 2010 |
| Priority date | Jul 3, 2003 |
| Publication date | Aug 2, 2016 |
| Grant date | Aug 2, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
There is described zeolites containing releasably adsorbed nitric oxide, methods of preparing the zeolites, methods of releasing the nitric oxide into a solution or into air and uses of the zeolites in therapy.
Opening claim text (preview).
The invention claimed is: 1. A method of releasing nitric oxide (NO) at body or room temperature from a zeolites comprising extra-framework cations, the method comprising the steps of: (i) providing a partially or fully dehydrated aluminosilicate zeolites comprising extra-framwork cations selected from the group consisting of Fe, Cu, Ru, Rh, Co, Ni, Zn, and Ag, the extra-framework cations being effective to chemically bind nitric oxide and having nitric oxide bound thereto, (ii) contacting the zeolites from (i) with moisture at body or room temperature, whereby nitric oxide is displaced from the zeolites and released, wherein the providing step comprises administering the zeolites to an animal subject either inside the animal subject or topically, and the contacting and release of nitric oxide occurs either inside the animal body or topically, respectively. 2. The method according to claim 1 , wherein the moisture is comprised within blood of the animal subject. 3. The method of claim 1 , wherein the providing step comprises topically administering the zeolites to an animal subject. 4. The method according to claim 3 , wherein the zeolites is administered in conjunction with a surgical procedure. 5. The method according to claim 1 , wherein the zeolites has an LTA (Linde Type A/Zeolite A) framework structure. 6. The method according to claim 1 , wherein the zeolites is in the form of a powder or a monolith. 7. The method according to claim 6 , wherein said monolith is formed by compression of a zeolites powder or comprises a powdered zeolites and a binder. 8. The method according to claim 7 , where the binder is selected from ceramic binders and polymeric binders. 9. The method according to claim 1 wherein the zeolites in step (i) is provided in sealed airtight packaging which is removed prior to use in the contacting step. 10. The method according to claim 1 , wherein the animal subject possesses a disease or medical condition selected from the group consisting of infection of the skin; Raynaud's disease; possession of a wound; restenosis; psoriasis, eczema, skin cancer (melanoma); severe foot or body odor, and methicillin-resistant Staphylococcus aureus infection. 11. The method according to claim 1 , wherein the zeolites in step (ii) is provided as part of a medical article selected from the group consisting of a stent, a catheter, a wound dressing, a bandage, a self-adhesive plaster and a patch. 12. The method of claim 1 , for use in a cosmetic or personal hygiene treatment of an individual, wherein step (i) comprises providing the zeolites in the form of a cosmetic preparation, deodorant, depilatory, or hair preparation. 13. The method of claim 1 , wherein the zeolites has a framework structure selected from LTA (Linde Type A/zeolite A), FAU (faujasite), MFI (ZSM-5) MOR (mordenite), FER (ferrierite), BEA (zeolites beta), PHI (zeolites Phi) and SAS (STA-6/St. Andrews Six). 14. The method of claim 1 , wherein the providing step comprises administering the zeolites to an animal subject inside the animal subject.
Related publications grouped by family.
Answers are generated from the same data shown on this page.